ZYRTEC (cetirizine hydrochloride) by Johnson & Johnson is mechanism of actions cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral h 1 receptors. First approved in 1996.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
ZYRTEC (cetirizine hydrochloride) is a second-generation selective peripheral H1-receptor antagonist indicated for allergic rhinitis and urticaria. It works by inhibiting histamine-mediated allergic responses without significant central nervous system penetration, providing non-sedating allergy relief.
As LOE approaches, the brand team is likely consolidating and transitioning focus to lifecycle extensions or defending market share against generic erosion.
Mechanism of Actions Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H 1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions
Worked on ZYRTEC at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moZYRTEC roles focus on defending market share and managing the transition to generic/OTC landscape rather than innovation or growth. Career advancement on this product likely involves managing decline, pricing strategy, and portfolio repositioning within J&J's consumer health or specialty divisions.